These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 854230)
21. Immune monitoring of cancer patients undergoing experimental immunotherapy. Shankar G; Salgaller ML Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653 [TBL] [Abstract][Full Text] [Related]
22. [Immunodiagnosis and its relevance in neoplastic disease, immunotherapy in neoplastic disease]. Kreienberg R Gynakologe; 1990 Jun; 23(3):122-9. PubMed ID: 2201596 [No Abstract] [Full Text] [Related]
23. [Effect of immune processes on the growth and regression of malignant tumors]. Russo V; Russo L Vopr Onkol; 1974; 20(6):68-75. PubMed ID: 4603500 [No Abstract] [Full Text] [Related]
24. [Problems of the immunotherapy of malignant neoplasma]. Trapeznikov NN; Iavorskiĭ VV Klin Med (Mosk); 1975 May; 52(5):15-22. PubMed ID: 1094178 [No Abstract] [Full Text] [Related]
25. Current condition and prognosis of tumor immunotherapy: a second opinion. Mastrangelo MJ; Berd D; Maguire HC Cancer Treat Rep; 1984 Jan; 68(1):207-19. PubMed ID: 6362864 [No Abstract] [Full Text] [Related]
26. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Lee Y; Bigner DD Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097 [TBL] [Abstract][Full Text] [Related]
27. Immunologic aspects of malignancy: Factors of concern in the prospective candidate for immunotherapy. Ablin RJ Allergol Immunopathol (Madr); 1975; 3(2):105-8. PubMed ID: 1155313 [No Abstract] [Full Text] [Related]
29. Novel antigenic markers of human tumor regression. Fareed GC; Mendiaz E; Sen A; Juillard GJ; Weisenburger TH; Totanes T J Biol Response Mod; 1988 Feb; 7(1):11-23. PubMed ID: 3373233 [TBL] [Abstract][Full Text] [Related]
30. In vitro methods for assessment of antibody-mediated tumor immunity. Levy NL; Amos DB; Solovieff GV; dos Reis AP Natl Cancer Inst Monogr; 1972 Dec; 35():5-11. PubMed ID: 4349154 [No Abstract] [Full Text] [Related]
32. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
34. Targeted cellular immunotherapy with bifunctional antibodies. Nelson H Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553 [TBL] [Abstract][Full Text] [Related]
35. [Chemo- and immunotherapy of malignant neoplasms]. Matthias M Z Arztl Fortbild (Jena); 1975 Jun; 69(11):580-4. PubMed ID: 1065149 [No Abstract] [Full Text] [Related]
36. The natural history of the antibody response to breast antigens. Boehm OR; Boehm BJ; Humphrey LJ Clin Exp Immunol; 1974 Jan; 16(1):31-9. PubMed ID: 4219760 [No Abstract] [Full Text] [Related]
37. Radiodiagnostic and radiotherapeutic implications of the recent discovery of a common malignant tumour antigen, CTA, absolutely unique to cancer cells. Kast RE Radiobiol Radiother (Berl); 1977; 18(4):536-44. PubMed ID: 601218 [No Abstract] [Full Text] [Related]
38. Monoclonal antibodies and immunologic approaches to malignant tumors. Ng AK; Giacomini P; Ferrone S Adv Intern Med; 1983; 28():253-76. PubMed ID: 6340428 [No Abstract] [Full Text] [Related]
39. [Immunology of malignant melanoma]. Misgeld V Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321 [No Abstract] [Full Text] [Related]